Yang et al. developed an amphiphilic drug-drug conjugate (CP-DDA) using derivatives of dasatinib (DAS, hydrophobic drug) and cisplatin (CP, hydrophilic anti-tumor drug), which could further self-assemble into stable carrier-free nanoparticles (CP-DDA NPs, Figure 7) [110]. The gene discussed is CP; the disease is neoplasm.